Articles from Curonix LLC

POMPANO BEACH, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in opioid-free chronic pain relief, today announced the launch of its next-generation wearable accessory for the Freedom® Peripheral Nerve Stimulator (PNS) System. This innovative wearable targets chronic pain in the head, neck, shoulder, and upper torso regions, with the potential to serve up to 235,000 patients annually1.

POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in relieving chronic pain without the use of opioids, proudly introduces NervPulse™ Therapy, an advanced, evidence-based programming platform designed to optimize peripheral nerve stimulation (PNS) therapy with the Freedom® PNS System. By delivering precise, nerve-specific stimulation, NervPulse Therapy sets a new standard in patient care, intending to improve clinical results and transform the patient experience.NervPulse Therapy is built from a robust clinical foundation of over 20,000 Freedom PNS procedures* and incorporates long-term data from 13 peer-reviewed publications and 450+ study patients. This extensive real-world and clinical experience has been transformed into an advanced, evidence-based solution developed in collaboration with leading physicians. By leveraging deep insights, NervPulse Therapy delivers standardized therapy programs for 26 individual peripheral nerves, enabling providers to implement the therapy with precision. These data-driven programs are designed to optimize device performance, improve procedural efficiency, and, most importantly, maximize patient outcomes by ensuring consistent, reproducible, and long-lasting therapeutic results and benefits."At Curonix, we are committed to redefining the boundaries of chronic pain management through innovation and evidence-based solutions," said Aure Bruneau, Chief Executive Officer of Curonix. "NervPulse Therapy is a transformative advancement in peripheral nerve stimulation, leveraging real-world data and clinical excellence to deliver targeted therapy. This approach enhances precision and efficiency for providers but, most importantly, it is intended to elevate the quality of treatment for patients suffering from chronic pain, today. NervPulse Therapy represents a major step forward in our mission to deliver innovative, life-changing relief for chronic pain patients."With NervPulse Therapy, Curonix continues to advance the field of PNS therapy by delivering targeted, nerve-specific programming that enhances outcomes and transforms the patient experience.

POMPANO BEACH, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in relieving chronic pain without the use of opioids, is proud to announce the expansion of MR labeling for its Freedom® Peripheral Nerve Stimulator (PNS) System to include full-body 3T MRI scans. The Freedom PNS System is the only PNS system cleared for applications throughout the entire body. Today, the Freedom PNS System is also the first and only permanent PNS system in the United States that is MR Conditional with the ability to scan throughout the body and over the implanted device at both 1.5T and 3T.* This marks another significant milestone in transforming the boundaries of chronic pain management by providing patients broader access to diagnostic imaging.

POMPANO BEACH, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Today, Curonix LLC highlights the newly released evidence-based consensus guidelines from the American Society of Interventional Pain Physicians (ASIPP®) validating the importance of PNS as a standard of care for chronic pain management, to optimize long-term patient outcomes.

POMPANO BEACH, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to relieving chronic pain without the use of opioids, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to expand the labeled indications for its minimally-invasive Freedom Peripheral Nerve Stimulator (PNS) System to include the craniofacial region. This makes Freedom PNS the first and only system cleared for full-body permanent PNS for the treatment of chronic, intractable pain of peripheral nerve origin.

POMPANO BEACH, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to easing chronic pain without the use of opioids, and Sure Med Compliance, a digital healthcare company focused on curbing opioid-related overdoses, announced today an exclusive partnership for large-scale, long-term PNS clinical data collection using Sure Med’s Perspectives in Care digital health platform.

POMPANO BEACH, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC, a leading peripheral nerve stimulation company celebrated its first anniversary. In November 2022, Curonix completed the purchase of substantially all assets, excluding liabilities, of Stimwave Technologies. During its first 12 months, Curonix:

POMPANO BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from chronic pain, announced the publication of a retrospective study in Neuromodulation reviewing the effectiveness of the Freedom® Peripheral Nerve Stimulator (PNS) System at the posterior tibial nerve for treating chronic foot pain related to peripheral neuropathy. The results showed that the Freedom PNS System successfully reduced pain scores and improved patient satisfaction. Patients also reported a considerable improvement in mobility and quality of life.

POMPANO BEACH, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC provided an update on the Medicare Physician Fee Schedule Proposed Rule published by the Centers for Medicare & Medicaid Services (CMS) on July 13, 2023, that provides additional coding clarity and positive proposed Medicare reimbursement rate updates.

Freedom® PNS is a proven, long-term effective treatment option for chronic pain